Merck Sharp + Dohme Corp.

Ravi Kurukulasuriya

Joseph A Kozlowski

David James Witter

Xianhai Huang

Kevin J Wilson

David L Sloman

Phieng Siliphaivanh

Christopher W Boyce

David Joseph Guerin

Raman Kumar Bakshi

Jason David Katz

Umar Faruk Mansoor

Yongqi Deng

Christopher Francis Thompson

Norman Kong

Mark E Scott

Hua Zhou

Yongxin Han

Christopher J Dinsmore

Lei Chen

Danielle Falcone

Qinglin Pu

Matthew H Daniels

Peter H Fuller

Wei Zhou

Salem Fevrier

Hongbo Zeng

Brendan O'Boyle

Kathryn Ann Lipford

Yumei Liu

Yunfeng Bai

Zhixiang Zheng

Ganesh Babu Karunakaran

Kun Liu

Jason D Brubaker

Jongwon Lim

Hongjun Zhang

Ling Tong

Shuwen He

Joey Lee Methot

Liangqin Guo

Joshua Close

Purakkattle J Biju

Milana M Maletic

Jianmin Fu

Nunzio Sciammetta

Abdelghani Achab

Catherine M White

Xavier Fradera

Matthew Lloyd Childers

Petr Vachal

Meredeth Ann McGowan

Ron Ferguson

Luis E Torres

Michelle Martinez

Jonathan E Wilson

Shuyi Tang

Judson E Richard

Angie R Angeles

Jayanth Thiruvellore Thatai

Meredeth A Mcgowan

Luis Torres

Bidhan A Shinkre

Hua Zhao

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. 

Compounds as indoleamine 2,3-dioxygenase inhibitors

The instant invention provides compounds of Formula (I) which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.

Geminally substituted cyanoethylpyrazolo pyridones as Janus kinase inhibitors

Provided are compounds of Formula I, a JAK inhibitor, and use thereof for the treatment of JAK-mediated diseases by the application. 

N-(2-cyano heterocyclyl) pyrazolo pyridones as janus kinase inhibitors

3,3'-Disubstituted indoline compounds, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis.

3,3'-disubstituted indolines as inhibitors of cholesterol ester transfer protein

Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1). 

Compounds that are ERK inhibitors

Disclosed are the ERK inhibitors of formula (1.0), having a pyrazolopyridine base structure, and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1.0). 

Growing community of inventors

Niantic, CT, United States of America

Ravi Kurukulasuriya